Trial Profile
Impact of the use of epoetin beta on sustained virological response in patients with hepatitis C virus treated with pegylated interferon alfa-2a plus ribavirin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Nov 2011
Price :
$35
*
At a glance
- Drugs Epoetin beta (Primary) ; Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PEGEPO
- 08 Nov 2011 Results presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
- 20 May 2011 New trial record